In this context, immunohistochemistry has been shown to be an effective approach with respect to identifying patients with NSCLC whose tumors harbor ALK gene rearrangements, and who are, therefore, suitable candidates for ALK tyrosine kinase receptor inhibitor therapy. Indeed, current NSCLC clinical ...